Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2003-05-08
2008-09-30
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S085100, C424S085200, C424S085500, C424S192100, C530S351000, C514S002600
Reexamination Certificate
active
07429384
ABSTRACT:
A recombinant chimeric antagonist formed by a 60 amino acid fragment of the N-terminal region of human interleukin 2 (IL-2) fused to the N-terminal of the extracellular region of the alpha subunit of the gamma IFN (IFN γ) receptor. In vitro this protein has a T cell growth stimulating activity, it inhibits the growth stimulating activity of IL-2 in T cells, it inhibits the induction of HLA-DR by IFN γ and it inhibits the antiproliferative activity of γ IFN. This invention can be applied in the field of medicine for the treatment of several pathologies such as autoimmune diseases, graft rejections, chronic inflammations, sepsis, ischemia and reperfusion syndrome and atherosclerosis.
REFERENCES:
patent: 5073627 (1991-12-01), Cosman et al.
patent: 0 393 502 (1990-10-01), None
patent: 0 614 981 (1994-09-01), None
patent: 0 621 338 (1994-10-01), None
patent: WO 94 21282 (1994-09-01), None
Fischer M, et al. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. 1997. Nature Biotechnology. vol. 15, No. 2, pp. 142-145.
Mickle J.E. et al. Genotype-phenotype relationships in cystic fibrosis. Med. Clin. N. Am. 2000. vol. 84, pp. 597-607.
Starnes H.F. et al. Anti-IL-6 monoclonal antibodies protect against lethalEscherichia coliinfection and lethal tumor necrosis factor-a challenge in mice. J. Immunol. 1990. vol. 145, pp. 4185-4191.
Doherty G.M. et al. Evidence for IFN-g as a mediator of the lethality of endotoxin and tumor necrosis factor-a. J. Immunol. 1992. vol. 149, pp. 1666-1670.
Bello, Y., et al., “The IFN-gamma pathophysiology. The role of soluble IFN-gamma-R alpha chain”,Biotecnologia Aplicada1995, 12(3):163-164.
Garcés Elizabeth Blanco
Rivero Iraldo Bello
Roll Giselle Pentón
Ruiz Yeny Torres
Saura Pedro López
Centro de Ingenieria Genetica y Biotecnologia
Hisong Bruce D.
Hoffman & Baron LLP
Landsman Robert
LandOfFree
Chimeric antagonist anth1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric antagonist anth1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric antagonist anth1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3987130